A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine

Steven Black, David P. Greenberg

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations

Abstract

Ideally, combination vaccines should not only be safe and effective, but also integrate smoothly into the vaccination schedule and provide advantages over the use of separately administered vaccines. Pentacel™ (Sanofl Pasteur Ltd., Toronto, Canada), a combination vaccine first licensed in Canada and subsequently in other countries, is immunogenic against diphtheria, tetanus, pertussis, pollo and Haemophilus influenzae type b when administered at 2, 4, 6 and 15-18 months of age. In published studies, the safety, immunogenicity and effectiveness of this combination vaccine were comparable with those of separately administered vaccines, with the advantage of a simplified dosing schedule.

Original languageEnglish
Pages (from-to)793-805
Number of pages13
JournalExpert Review of Vaccines
Volume4
Issue number6
DOIs
StatePublished - 1 Dec 2005
Externally publishedYes

Keywords

  • DTaP
  • Diphtheria tetanus acellular pertussis vaccine
  • Haemophilus influenzae type b (Hib) vaccine
  • Immunizations
  • Inactivated poliovirus vaccine
  • Pentacel™
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine'. Together they form a unique fingerprint.

Cite this